Skip to main content
FinSpry Logo
FinSpry
NCEL logo
NCEL
(NASDAQ)
NewcelX Ltd.
$3.18-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

NewcelX (NCEL) Company Profile

Complete business overview, executive team, trading details, and corporate information.

NewcelX Ltd.
NCEL•Nasdaq Stock Market•Healthcare•Biotechnology

About NewcelX

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORonen Twito
Founded2008
Employees15
CountrySwitzerland
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitenewcelx.com
Phone41 44 512 21 50
Address
The Circle 6 Zurich, 8058 Switzerland

Corporate Identifiers

CIK0001783036
CUSIPH5835A109
ISINCH1442297896

Leadership Team & Key Executives

Ronen Twito CPA
Chief Executive Officer and Executive Chairman
Prof. Michel Revel M.D., Ph.D.
Co-Founder, Chief Scientist, Head of the Scientific Advisory Board and Director
Yossi Ben-Yossef
Honorary President and Strategic Consultant
Omri Hagai
Chief Financial Officer
Alexander C. Zwyer M.B.A.
Chief Business Officer and Executive Director
Dr. Eric Konofal M.D., Ph.D.
Head of Doxa Program
Prof. Ariel Revel M.D.
Director of Medical Affairs